↓ Skip to main content

Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

Overview of attention for article published in BMC Cancer, August 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
4 tweeters
patent
1 patent

Citations

dimensions_citation
47 Dimensions

Readers on

mendeley
64 Mendeley
Title
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
Published in
BMC Cancer, August 2014
DOI 10.1186/1471-2407-14-570
Pubmed ID
Authors

Christopher Bryant, Rebecca Rawlinson, Andrew J Massey

Abstract

Chk1 inhibitors are currently in clinical trials as putative potentiators of cytotoxic chemotherapy drugs. Chk1 inhibitors may exhibit single agent anti-tumor activity in cancers with underlying DNA repair, DNA damage response or DNA replication defects.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Mexico 1 2%
United States 1 2%
Unknown 61 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 25%
Student > Ph. D. Student 15 23%
Student > Bachelor 9 14%
Other 5 8%
Unspecified 4 6%
Other 15 23%
Readers by discipline Count As %
Agricultural and Biological Sciences 21 33%
Medicine and Dentistry 12 19%
Biochemistry, Genetics and Molecular Biology 12 19%
Unspecified 7 11%
Pharmacology, Toxicology and Pharmaceutical Science 5 8%
Other 7 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 September 2017.
All research outputs
#2,412,343
of 11,707,803 outputs
Outputs from BMC Cancer
#529
of 4,301 outputs
Outputs of similar age
#36,143
of 190,749 outputs
Outputs of similar age from BMC Cancer
#16
of 125 outputs
Altmetric has tracked 11,707,803 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,301 research outputs from this source. They receive a mean Attention Score of 3.9. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 190,749 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 125 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.